{"date":"2025-09-30","count":34,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6734-2025-09-30-2221-1p6tsqi","company_id":"6734","company":"安盛生","market":"興櫃","industry":"生技醫療","date":"2025-09-30","time":"22:21:47","subject":"公告本公司114年8月份自結財務報告之負債比率、流動比率、速動比率、預估未來三個月現金收支情形及銀行可使用融資額度情形","clause":"第44款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：安盛生（6734），2025-09-30 22:21，「公告本公司114年8月份自結財務報告之負債比率、流動比率、速動比率、預估未來三個月現金收支情形及銀行可使用融資額度情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6748-2025-09-30-2019-1qjw9hp","company_id":"6748","company":"亞果生醫","market":"興櫃","industry":"生技醫療","date":"2025-09-30","time":"20:19:11","subject":"公告本公司取得醫療器材品質管理系統準則(QMS)廠址範圍擴增之製造許可","clause":"第44款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：亞果生醫（6748），2025-09-30 20:19，「公告本公司取得醫療器材品質管理系統準則(QMS)廠址範圍擴增之製造許可」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6703-2025-09-30-1957-1kyvvmf","company_id":"6703","company":"軒郁","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"19:57:39","subject":"代重要子公司新普利股份有限公司出租不動產使用權資產予關係人","clause":"第20款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：軒郁（6703），2025-09-30 19:57，「代重要子公司新普利股份有限公司出租不動產使用權資產予關係人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6885-2025-09-30-1850-1i7x99z","company_id":"6885","company":"全福生技","market":"上市","industry":"生技醫療","date":"2025-09-30","time":"18:50:21","subject":"公告本公司開發中新藥BRM421用於治療乾眼症第III期臨床試驗計畫書已向美國食品藥物管理局(US FDA)提出申請","clause":"第10款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：全福生技（6885），2025-09-30 18:50，「公告本公司開發中新藥BRM421用於治療乾眼症第III期臨床試驗計畫書已向美國食品藥物管理局(US FDA)提出申請」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4155-2025-09-30-1807-57zjbn","company_id":"4155","company":"訊映","market":"上市","industry":"生技醫療","date":"2025-09-30","time":"18:07:09","subject":"公告本公司副總經理異動","clause":"第8款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：訊映（4155），2025-09-30 18:07，「公告本公司副總經理異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-09-30-1758-1bnzcw8","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-09-30","time":"17:58:23","subject":"公告對霖揚生技之資金貸與轉現金增資案","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-09-30 17:58，「公告對霖揚生技之資金貸與轉現金增資案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4168-2025-09-30-1731-homgw","company_id":"4168","company":"醣聯","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"17:31:27","subject":"公告本公司國內第四次有擔保轉換公司債轉換價格調整","clause":"第53款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：醣聯（4168），2025-09-30 17:31，「公告本公司國內第四次有擔保轉換公司債轉換價格調整」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6130-2025-09-30-1728-uoqaqq","company_id":"6130","company":"上亞科技","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"17:28:34","subject":"公告本公司會計主管辭職","clause":"第8款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：上亞科技（6130），2025-09-30 17:28，「公告本公司會計主管辭職」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-09-30-1727-1o5mfha","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-09-30","time":"17:27:57","subject":"公告本公司策略長異動","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-09-30 17:27，「公告本公司策略長異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-09-30-1726-uqazlc","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-09-30","time":"17:26:09","subject":"修改2025年度員工認股權憑證發行及認股辦法","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-09-30 17:26，「修改2025年度員工認股權憑證發行及認股辦法」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6949-2025-09-30-1706-100esni","company_id":"6949","company":"沛爾生醫*-創","market":"上市","industry":"生技醫療","date":"2025-09-30","time":"17:06:40","subject":"公告本公司研發主管異動","clause":"第8款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：沛爾生醫*-創（6949），2025-09-30 17:06，「公告本公司研發主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6814-2025-09-30-1659-1pzjlpi","company_id":"6814","company":"路迦生醫","market":"興櫃","industry":"生技醫療","date":"2025-09-30","time":"16:59:42","subject":"公告本公司預估未來三個月現金收支情形及銀行可使用融資額度情形","clause":"第44款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：路迦生醫（6814），2025-09-30 16:59，「公告本公司預估未來三個月現金收支情形及銀行可使用融資額度情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4745-2025-09-30-1653-4e78ik","company_id":"4745","company":"合富-KY","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"16:53:28","subject":"代重要子公司合富（中國）醫療科技股份有限公司公告召開2025年半年度業績說明會","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：合富-KY（4745），2025-09-30 16:53，「代重要子公司合富（中國）醫療科技股份有限公司公告召開2025年半年度業績說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4175-2025-09-30-1650-ag0ktz","company_id":"4175","company":"杏一","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"16:50:52","subject":"本公司受邀參加永豐金證券舉辦之線上法人說明會","clause":"第12款","fact_date":"2025-10-01","cite_as":"公開資訊觀測站重大訊息：杏一（4175），2025-09-30 16:50，「本公司受邀參加永豐金證券舉辦之線上法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6838-2025-09-30-1622-p67uuk","company_id":"6838","company":"台新藥","market":"上市","industry":"生技醫療","date":"2025-09-30","time":"16:22:53","subject":"公告本公司內部稽核主管異動","clause":"第8款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：台新藥（6838），2025-09-30 16:22，「公告本公司內部稽核主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1795-2025-09-30-1608-1hkj5dk","company_id":"1795","company":"美時","market":"上市","industry":"生技醫療","date":"2025-09-30","time":"16:08:53","subject":"係因本公司有價證券於集中交易市場達公布注意交易資訊標準，故公布相關財務業務等重大訊息，以利投資人區別瞭解","clause":"第51款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：美時（1795），2025-09-30 16:08，「係因本公司有價證券於集中交易市場達公布注意交易資訊標準，故公布相關財務業務等重大訊息，以利投資人區別瞭解」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4166-2025-09-30-1545-3bed5x","company_id":"4166","company":"友霖","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"15:45:44","subject":"公告本公司財務主管暨會計主管異動","clause":"第8款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：友霖（4166），2025-09-30 15:45，「公告本公司財務主管暨會計主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6696-2025-09-30-1536-1veab7h","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2025-09-30","time":"15:36:55","subject":"代重要子公司Belite公告重新指派轉投資子公司Belite Bio(Shanghai) Limited倍亮生技醫藥(上海)有限公司董事及代表人","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2025-09-30 15:36，「代重要子公司Belite公告重新指派轉投資子公司Belite Bio(Shanghai) Limited倍亮生技醫藥(上」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4188-2025-09-30-1525-w5f2h9","company_id":"4188","company":"安克","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"15:25:03","subject":"代子公司(聲博科技)公告法人監察人改派代表人","clause":"第6款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：安克（4188），2025-09-30 15:25，「代子公司(聲博科技)公告法人監察人改派代表人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1784-2025-09-30-1503-1qtnfft","company_id":"1784","company":"訊聯","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"15:03:02","subject":"衛福部核准本公司與佛教慈濟醫療財團法人台北慈濟醫院合作之自體脂肪幹細胞治療退化性關節炎及膝關節軟骨缺損計畫","clause":"第53款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：訊聯（1784），2025-09-30 15:03，「衛福部核准本公司與佛教慈濟醫療財團法人台北慈濟醫院合作之自體脂肪幹細胞治療退化性關節炎及膝關節軟骨缺損計畫」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6130-2025-09-30-1501-1h3luiv","company_id":"6130","company":"上亞科技","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"15:01:35","subject":"公告本公司財務主管辭職","clause":"第8款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：上亞科技（6130），2025-09-30 15:01，「公告本公司財務主管辭職」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6130-2025-09-30-1500-8y17bc","company_id":"6130","company":"上亞科技","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"15:00:40","subject":"公告本公司治理主管辭職","clause":"第8款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：上亞科技（6130），2025-09-30 15:00，「公告本公司治理主管辭職」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6130-2025-09-30-1500-10hqkh5","company_id":"6130","company":"上亞科技","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"15:00:07","subject":"公告本公司薪酬委員新任","clause":"第6款","fact_date":"2025-09-25","cite_as":"公開資訊觀測站重大訊息：上亞科技（6130），2025-09-30 15:00，「公告本公司薪酬委員新任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6130-2025-09-30-1459-1io8qbu","company_id":"6130","company":"上亞科技","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"14:59:35","subject":"公告本公司審計委員新任","clause":"第6款","fact_date":"2025-09-25","cite_as":"公開資訊觀測站重大訊息：上亞科技（6130），2025-09-30 14:59，「公告本公司審計委員新任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6130-2025-09-30-1458-g1rrhx","company_id":"6130","company":"上亞科技","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"14:58:40","subject":"代重要子公司諾肯科技(股)公司公告114年4月18日董事會重要決議不配發股利","clause":"第14款","fact_date":"2025-04-18","cite_as":"公開資訊觀測站重大訊息：上亞科技（6130），2025-09-30 14:58，「代重要子公司諾肯科技(股)公司公告114年4月18日董事會重要決議不配發股利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6130-2025-09-30-1451-uvoz0i","company_id":"6130","company":"上亞科技","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"14:51:54","subject":"代重要子公司諾肯科技(股)公司公告114年員工認股權憑證轉換普通股之基準日(更正事實發生日)","clause":"第11款","fact_date":"2025-04-18","cite_as":"公開資訊觀測站重大訊息：上亞科技（6130），2025-09-30 14:51，「代重要子公司諾肯科技(股)公司公告114年員工認股權憑證轉換普通股之基準日(更正事實發生日)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6130-2025-09-30-1450-u7t6v2","company_id":"6130","company":"上亞科技","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"14:50:53","subject":"代重要子公司諾肯科技(股)公司公告114年4月18日董事會重要決議事項(更正事實發生日)","clause":"第53款","fact_date":"2025-04-18","cite_as":"公開資訊觀測站重大訊息：上亞科技（6130），2025-09-30 14:50，「代重要子公司諾肯科技(股)公司公告114年4月18日董事會重要決議事項(更正事實發生日)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4117-2025-09-30-1449-bgpotu","company_id":"4117","company":"普生","market":"興櫃","industry":"生技醫療","date":"2025-09-30","time":"14:49:31","subject":"公告本公司114年8月份自結合併財務報告之負債比率、流動比率及速動比率","clause":"第44款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：普生（4117），2025-09-30 14:49，「公告本公司114年8月份自結合併財務報告之負債比率、流動比率及速動比率」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6785-2025-09-30-1444-7ammwo","company_id":"6785","company":"昱展新藥","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"14:44:34","subject":"公告本公司收到「LONG-ACTING INJECTABLE FORMULATIONSAND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES」歐洲專利即將核准通知書。","clause":"第53款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：昱展新藥（6785），2025-09-30 14:44，「公告本公司收到「LONG-ACTING INJECTABLE FORMULATIONSAND CRYSTALLINE F」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4117-2025-09-30-1439-1l248wr","company_id":"4117","company":"普生","market":"興櫃","industry":"生技醫療","date":"2025-09-30","time":"14:39:46","subject":"公告本公司114年現金增資收足股款暨增資基準日","clause":"第44款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：普生（4117），2025-09-30 14:39，「公告本公司114年現金增資收足股款暨增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6931-2025-09-30-1415-1efbul1","company_id":"6931","company":"青松健康","market":"上市","industry":"生技醫療","date":"2025-09-30","time":"14:15:04","subject":"代子公司青松長照社團法人公告向關係人取得使用權資產","clause":"第20款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：青松健康（6931），2025-09-30 14:15，「代子公司青松長照社團法人公告向關係人取得使用權資產」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2025-09-30-0856-t3g9ya","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2025-09-30","time":"08:56:10","subject":"公告本公司醫療長(CMO)異動(更正公告)","clause":"第11款","fact_date":"2025-09-30","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2025-09-30 08:56，「公告本公司醫療長(CMO)異動(更正公告)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6875-2025-09-30-0609-1k6j2l8","company_id":"6875","company":"國邑*","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"06:09:35","subject":"本公司吸入新藥 L608 臨床一期試驗成果於2025年歐洲呼吸學會（ERS 2025）發表，展示其在CTEPH治療中的潛力","clause":"第53款","fact_date":"2025-09-28","cite_as":"公開資訊觀測站重大訊息：國邑*（6875），2025-09-30 06:09，「本公司吸入新藥 L608 臨床一期試驗成果於2025年歐洲呼吸學會（ERS 2025）發表，展示其在CTEPH治療中的潛」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2025-09-30-0607-9jdyfi","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2025-09-30","time":"06:07:33","subject":"代子公司Handa Oncology公告，治療癌症之505(b)(2)新藥HND-039向美國FDA提出新藥查驗登記申請(NDA)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2025-09-30 06:07，「代子公司Handa Oncology公告，治療癌症之505(b)(2)新藥HND-039向美國FDA提出新藥查驗登記申請」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}